Physician
Oncology
Dr. David Friedland, MD
Doctor David Friedland, MD is an expert in the field of Oncology. He graduated from University of Maryland School of Medicine. University of Maryland School of Medicine has a rank of 37 in research and a 52 in primary care He received 3 awards: "Regional Top Doctor", "CMS Meaningful Use Stage 1 Certification" and "Top MD". David Friedland is a published physician. He has 39 papers published. The most current publication "Molecular alterations to human chromosome 3p loci in neuroendocrine lung tumors." He is registered with Medicare.
Publications
- Population Pharmacokinetics of Pegylated Liposomal CKD-602 (S-CKD602) in Patients With Advanced Malignancies.
- Bidirectional pharmacodynamic interaction between pegylated liposomal CKD-602 (S-CKD602) and monocytes in patients with refractory solid tumors.
- Phase I and pharmacokinetic study of pegylated liposomal CKD-602 in patients with advanced malignancies.
- Bevacizumab and irinotecan therapy in glioblastoma multiforme: a series of 13 cases.
- A phase I study of 17-allylamino-17-demethoxygeldanamycin combined with paclitaxel in patients with advanced solid malignancies.
- Renal cell carcinoma from a transplanted allograft: two case reports and a review of the literature.
- Radiosurgery for the treatment of spinal lung metastases.
- Long-term survivors after gamma knife radiosurgery for Brain metastases.
- Stereotactic radiosurgery for spinal metastases from renal cell carcinoma.
- Phase I and pharmacologic study of intermittently administered 9-nitrocamptothecin in patients with advanced solid tumors.
- A phase II evaluation of weekly paclitaxel plus carboplatin in advanced urothelial Cancer.
- Hypersensitivity reactions from taxol and etoposide.
- Spread of the Spanish multi-resistant serotype 23F clone of Streptococcus pneumoniae to Seoul, Korea.
- First hints in non-small cell lung Cancer (NSCLC).
- CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure inf...
- Spontaneous CD4+ T cell responses against TRAG-3 in patients with melanoma and breast Cancers.
- Phase I clinical/pharmacokinetic and pharmacodynamic trial of the c-raf-1 antisense oligonucleotide ISIS 5132 (CGP 69846A).
- Endostatin plus interferon-alpha2b therapy for metastatic melanoma: a novel combination of antiangiogenic and immunomodulatory agents.
- A phase II trial of docetaxel (Taxotere) in hormone-refractory prostate Cancer: correlation of antitumor effect to phosphorylation of Bcl-2.
- Phase II trial of all-trans retinoic acid in metastatic non-small cell lung Cancer.
- A phase I/II study of trimetrexate and capecitabine in patients with advanced refractory colorectal Cancer.
- Phase I and pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with refractory advanced Cancers.
- Phase II study of everolimus (RAD001) in previously treated small cell lung Cancer.
- A phase II study of weekly paclitaxel/estramustine/carboplatin in hormone-refractory prostate Cancer.
- A Phase I pharmacokinetic and pharmacodynamic study of PX-12, a novel inhibitor of thioredoxin-1, in patients with advanced solid tumors.
- Pharmacokinetic study of pegylated liposomal CKD-602 (S-CKD602) in patients with advanced malignancies.
- What should be the routine follow-up after definitive therapy of localized lung Cancer?
- Perioperative therapy of non-small cell lung Cancer: a review of adjuvant and neoadjuvant approaches.
- Recurrent methicillin-resistant Staphylococcus aureus osteomyelitis: combination antibiotic therapy with evaluation by serum bactericidal titers.
- New chemotherapy agents in the treatment of advanced non-small cell lung Cancer: an update including data from the Seventh World Conference on Lung Cancer.
- Properties of chicken erythrocyte delta-aminolevulinate synthase.
- Biogenesis of liver delta-aminolevulinate synthase. The role of cAMP in the induction.
- The role of oral etoposide in non-small cell lung Cancer.
- Molecular alterations to human chromosome 3p loci in neuroendocrine lung tumors.
- Small-cell lung Cancer: a perspective on the past and a preview of the future.
- Phase I study of weekly (day 1 and 8) docetaxel in combination with capecitabine in patients with advanced solid malignancies.
- Phase II study of carboxyamidotriazole in patients with advanced renal cell carcinoma refractory to immunotherapy: E4896, an Eastern Cooperative Oncology Group Study.
- Extraosseous osteosarcoma of the esophagus: a case report.
Schools
Mount Sinai School Of Medicine Of New York University
Mt Sinai
Johns Hopkins
Procedures Preformed
- Adult Hearing Loss Rehabilitation
- Cochlear Implant Insertion
- Craniectomy, Craniotomy, Surgery of Skull Base, Neuroendoscopy
- Diagnostic Nasal and-or Sinus Endoscopy
- View All
Conditions Treated
- Acoustic Neuroma
- Acute Laryngitis
- Acute Sinusitis
- Allergic Rhinitis
- View All
Doctors Specialties
- Neurotology
- Oncology
Accepted Insurances
- Aetna
- American Republic
- Anthem Blue Cross Blue Shield HMO
- Anthem Blue Cross Blue Shield PPO
- Blue Preferred Plus POS
- Assurant Health
- Blue Card PPO
- Blue Cross Blue Shield of Illinois PPO
- Blue Cross Accord
- CHAMPVA
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Commercial Insurance Company
- CoreSource
- First Health (Coventry Health Care) PPO
- Golden Rule
- GEHA
- Medicare Advantage PFFS
- Choice Care PPO
- Medicare MCR
- MultiPlan
- Principal Life
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- United Healthcare
- Universal American
- Wisconsin Physicians Service
Awards
- Regional Top Doctor
- CMS Meaningful Use Stage 1 Certification
- Top MD
Education
-
University of Pennsylvania Health System -
University of Maryland School of Medicine
Hospital
-
UPMC Presbyterian Shadyside
Drug Facts
| NPI NUMBER | 1760433148 | |
| NPPES Provider LastName | FRIEDLAND | |
| NPPES Provider FirstName | DAVID | |
| NPPES Provider ZIPCode | 532263522 | |
| NPPES Provider State | WI | |
| Specialty Description | Otolaryngology | |
| Total Claim Count | 39.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1760433148 |
| Last Name Of The Provider | FRIEDLAND |
| First Name Of The Provider | DAVID |
| View All |
Similar Doctors
|
Dr. Sumana Devata, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Matthew R. Zibelman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nicholas P. Webber, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. John Charlson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Matthew J. Riese, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Paul Ritch, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John P. Hanson Jr., MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Husam S. Tarawneh, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Faisal Saghir, MD
This Doctor is OpenDoctor Recommended.
|